DDInter1042 DDInter603
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
Droperidol {u} (Compound) resembles {v} (Compound) Haloperidol
Droperidol {u} (Compound) resembles {v} (Compound) Fluspirilene
Droperidol {u} (Compound) binds {v} (Gene) ADRA1A
Droperidol {u} (Compound) is included by {v} (Pharmacologic Class) Dopamine D2 Antagonists
Droperidol {u} (Compound) downregulates {v} (Gene) CHIC2
Droperidol {u} (Compound) causes {v} (Side Effect) Altered state of consciousness
Droperidol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Droperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Droperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Droperidol {u} may lead to a major life threatening interaction when taken with {v} Naloxone
Droperidol (Compound) resembles Haloperidol (Compound)
Droperidol (Compound) resembles Fluspirilene (Compound)
Droperidol (Compound) binds ADRA1A (Gene)
Droperidol (Compound) is included by Dopamine D2 Antagonists (Pharmacologic Class)
Droperidol (Compound) downregulates CHIC2 (Gene)
Droperidol (Compound) causes Altered state of consciousness (Side Effect)
Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Droperidol may lead to a major life threatening interaction when taken with Naloxone